Is thymulin FDA-approved, and what does the research show?

What is thymulin?

Thymulin is a hormone made only by the epithelial cells of the thymus, the gland behind the breastbone where T cells mature ¹. It is a peptide of nine amino acids, a nonapeptide, which on its own is inactive ¹. Bound to one zinc ion it takes the shape that gives it its biological activity ¹. Its peptide part is called FTS, from the French for serum thymic factor (facteur thymique sérique) ¹, ⁸.

In people, zinc deficiency lowers the activity of thymulin in the blood ⁹. Thymulin levels also fall with age ⁶. One review puts the decline from about age 20, with the hormone no longer detectable between the fifth and sixth decade of life ⁸. The synthetic version used in trials was called nonathymulin ⁴.

Is thymulin FDA-approved?

Thymulin is not FDA-approved: Drugs@FDA lists no approved thymulin product as of November 9, 2026 ². It is a research compound whose human trials ended in the 1980s without an approved medicine ⁴, ⁵. FDA keeps a list of bulk drug substances nominated for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act ³. Section 503A is the part of the law that covers pharmacy compounding, and the list sorts substances into three categories ³.

On that list, updated May 14, 2026, thymulin acetate sits in Category 3, headed "Bulk Drug Substances Nominated Without Adequate Support" ³. FDA's January 2025 interim policy explains the category: these substances "were nominated with insufficient supporting information for FDA to evaluate them" and "can be renominated with sufficient supporting information" ¹⁰. The same policy says FDA "does not intend to take action against a State-licensed pharmacy" compounding with a substance that "appears in 503A Category 1", under its conditions ¹⁰. That statement names Category 1 only; thymulin acetate is in Category 3 ³, ¹⁰.

Thymulin is not on FDA's list of substances nominated for outsourcing facilities under section 503B, updated March 21, 2025 ¹¹. FDA's page on bulk substances with significant safety risks carries no entry for it. No FDA warning letter naming thymulin was found in FDA's warning-letter search on November 9, 2026. No lawful route to thymulin as a medicine appears in any source opened.

See the FDA status of every peptide, updated weekly.

How does thymulin work?

The mechanism is described in reviews and animal work, with little tested in people. Discovered in the early 1970s, thymulin was characterized as a thymic hormone involved in the differentiation of T cells, inside and outside the thymus ¹. Its activity depends on zinc: in a study that fed healthy volunteers a low-zinc diet, thymulin activity fell within eight to twelve weeks, before zinc in plasma did ¹². In 27 patients with Crohn's disease in remission, three months of oral zinc restored low plasma thymulin only in the group given the higher dose ¹³.

The 2009 review proposes that thymulin also acts on the pituitary gland, the hormone gland at the base of the brain ¹. In rat pituitary tissue it released two pituitary hormones, luteinizing hormone and ACTH ¹. In rats, thymulin and a related peptide showed anti-inflammatory and analgesic effects in the brain ¹.

In 2026, a study in mice reported that thymulin suppressed inflammatory signaling in myeloid cells, a class of white blood cells, by inhibiting NF-κB, a signaling pathway that drives inflammation ⁶. The same study found more of these inflammatory cells in aged mice and in samples from older people ⁶. Nothing from that work has been tested as a treatment in people ⁶.

What does the research show?

Studied in people: two randomized, double-blind, placebo-controlled trials of nonathymulin in rheumatoid arthritis, published in 1987 ⁴. The trials compared three daily dose schedules against placebo ⁴. In the dose group the authors judged best, 56 percent of patients improved on a global assessment, against 17 percent on placebo ⁴. The abstract reports "minimal adverse effects" and no clear change in immune measures ⁴.

Studied in people: a randomized, double-blind, placebo-controlled pilot trial in multiple sclerosis, published in 1989 ⁵. Forty matched patients with progressing disease and moderate disability received nonathymulin or placebo under the skin for six months, then were followed for six more ⁵. Disability scores, walking and functional scales did not differ between the groups, and the authors concluded it "is not effective" in that population ⁵.

Studied in people: a 1982 case series of three children with immune deficiency given synthetic thymulin intravenously ⁷. Their doctors reported fewer and milder infections, and the appearance of serum IgA, an antibody class, in two who had none ⁷. The report had no comparison group, so it cannot show whether the treatment worked ⁷.

Studied in mice for inflammation with age and for cancer immunotherapy, in the 2026 paper ⁶. There, thymulin improved tumor control and survival and made tumors more responsive to an anti-PD-L1 antibody, a cancer immunotherapy drug, in an age-dependent way ⁶. Studied in rats for inflammation and pain, as the 2009 review describes ¹.

No human trial of thymulin published since 1989 was found among the sources opened on November 9, 2026. ClinicalTrials.gov listed no study testing thymulin as a treatment on that date ¹⁴. The questions a modern trial would answer, including what thymulin does in healthy adults or in aging, have not been studied.

What are the side effects?

What is documented in people comes from three trials, two of unreported size and one of 40, and a three-child case series, all nearly forty years old. The rheumatoid arthritis trials reported "minimal adverse effects" ⁴. The multiple sclerosis trial, of 40 patients given nonathymulin or placebo for six months, recorded "no significant side effects" ⁵. Neither abstract names the effects seen, their rates, or any withdrawals ⁴, ⁵. The 2009 review states that thymulin "has no known toxic effects even at high doses," a claim it makes without citing a study, in a discussion of gene therapy in rodents ¹.

In rats, a low dose of thymulin injected into the abdomen produced heightened sensitivity to heat and pressure, and raised inflammatory signals in the liver ¹⁵. The same peptide reduced inflammatory pain in other rat studies ¹. No FDA safety statement about thymulin was found. It is not on the agency's safety-risks page, and Category 3 means a nomination without adequate support, not a safety finding ³, ¹⁰. What thymulin does in a person over months or years, or alongside other medicines, has not been studied in any source opened.

In sport

Thymulin is not named on WADA's 2026 Prohibited List ¹⁶. WADA, the World Anti-Doping Agency, also has a class S0, "Non-approved substances," prohibited at all times ¹⁶. It covers "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times" ¹⁶.

FDA's records were read for the status above; no other country's regulator was checked ². Whether S0 covers thymulin is a question for an athlete's anti-doping organization.

What JumpstartMD offers

JumpstartMD does not prescribe thymulin. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.